Skip to main content

Christopher Lewis Reading, PhD

Chief Scientific Officer at Harbor Therapeutics, Inc.

Location: San Diego, CA United States

Associated Grants

  • Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.